8-K filing — Century Therapeutics, Inc. (IPSC)
Filed: 2026-08-12 AccNo: 0001104659-26-094533 Size: 6 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Century Therapeutics Announces Presentation Of New Preclinical Data At American Diabetes Association Sessions Supporting CNTY-813 Novel Islet Cell Replacement Treatment
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Century Therapeutics Q2 EPS $(0.17) Misses $(0.14) Estimate
Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 55.26 percent increase over losses of $(0.38) per
Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
US stock futures up, Dow futures gain 100+ points. Concentrix Corp (CNXC) shares down 24% after weak Q2 results and lowered FY26 guidance. Other stocks also decline in pre-market trading.
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected first-quarter financial results. Other big gainers in today's session include FuelCell Energy Inc (NASDAQ: FCEL) up 17.6%, BitVentures Limited (NASDAQ: BVC) up 14.1%, and ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) up 10.3% after receiving a positive recommendation for a market authorization in Europe.